Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up - Still a Buy?

Key Points

• Capricor Therapeutics shares gapped higher, opening at $10.77 versus a prior close of $9.91, after investors responded favorably to an August FDA update on the ongoing review of Deramiocel.
• Analyst sentiment is mixed: Piper Sandler and Cantor Fitzgerald upgraded the stock, while several firms downgraded it. The consensus rating remains Hold, with a $29.15 price target.
• The company missed quarterly earnings expectations, reporting a loss of $0.70 per share versus the projected $0.59 loss. Insiders sold roughly $759,000 of stock during the last quarter, while institutional investors own 21.68% of shares.

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $9.91, but opened at $10.77. Capricor Therapeutics shares last traded at $10.2510, with a volume of 1,487,566 shares traded.

Trending Headlines about Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor shares rose after an August FDA update, suggesting investors viewed the latest regulatory communication as somewhat less negative or more constructive than previously feared. The FDA’s ongoing review of Deramiocel remains the primary potential catalyst for CAPR. Capricor Therapeutics shares rise following August FDA update

Wall Street Analysts Forecast Growth

CAPR has been the topic of several research reports. Piper Sandler upgraded shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday. Alliance Global Partners cut shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 target price on the stock. in a report on Tuesday, July 28th. Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Friday, August 14th. Roth Capital cut Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 price target for the company. in a research note on Monday, July 27th. Finally, Maxim Group downgraded Capricor Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, July 30th. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $29.15.

Capricor Therapeutics Price Performance

The firm's 50-day simple moving average is $14.07 and its 200 day simple moving average is $24.19. The firm has a market capitalization of $593.90 million, a price-to-earnings ratio of -4.18 and a beta of 0.54.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). As a group, research analysts predict that Capricor Therapeutics, Inc. will post -1.72 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at approximately $340,954.74. This represents a 68.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 25,000 shares of company stock worth $759,158 in the last quarter. Insiders own 9.20% of the company's stock.

Institutional Trading of Capricor Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. raised its holdings in Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock worth $37,000 after purchasing an additional 2,786 shares during the last quarter. ACT Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $43,000. KBC Group NV bought a new position in Capricor Therapeutics during the first quarter worth $44,000. Tower Research Capital LLC TRC lifted its holdings in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock valued at $67,000 after buying an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC acquired a new position in Capricor Therapeutics in the third quarter valued at $92,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source